Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy

[Image: see text] Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become standard of care for certain types of cancers. However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies. Combination therapy strategies...

詳細記述

保存先:
書誌詳細
出版年:ACS Med Chem Lett
主要な著者: Zhang, Hongjun, Liu, Kun, Pu, Qinglin, Achab, Abdelghani, Ardolino, Michael J., Cheng, Mangeng, Deng, Yongqi, Doty, Amy C., Ferguson, Heidi, Fradera, Xavier, Knemeyer, Ian, Kurukulasuriya, Ravi, Lam, Yu-hong, Lesburg, Charles A., Martinot, Theodore A., McGowan, Meredeth A., Miller, J. Richard, Otte, Karin, Biju, Purakattle J., Sciammetta, Nunzio, Solban, Nicolas, Yu, Wensheng, Zhou, Hua, Wang, Xiao, Bennett, David Jonathan, Han, Yongxin
フォーマット: Artigo
言語:Inglês
出版事項: American Chemical Society 2019
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6862341/
https://ncbi.nlm.nih.gov/pubmed/31749906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00344
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料